尤瑞克林联合单唾液酸四己糖神经节苷脂治疗急性脑梗死的临床研究  

Clinical study of efficacy of urinary kallikrein combined with monosialotetrahexosyl ganglioside for acute cerebral infarction

作　　者：邓珊[1] 阳洪[1] 蒋祝昌[1] 翁保慧[1] 陈仕检[1] 

机构地区：[1]广西医科大学第四附属医院神经内科,柳州545005

出　　处：《右江医学》2015年第6期676-679,共4页Chinese Youjiang Medical Journal

摘　　要：目的观察尤瑞克林联合单唾液酸四己糖神经节苷脂治疗急性脑梗死的疗效及安全性。方法将100例脑梗死患者随机分为两组各50例,对照组根据病情给予相应基础药物治疗。观察组在对照组基础上,给予尤瑞克林0.15 PNAU静脉滴注,每日1次,单唾液酸四己糖神经节苷脂100 mg静脉滴注,每日1次,疗程为21天。结果治疗第21天后,观察组的疗效显著优于对照组,差异有统计学意义(P<0.01)。两组患者治疗前的美国国立卫生研究院卒中量表(NIHSS)评分和日常生活能力(BI)评分比较差异无统计学意义(P>0.05);两组患者治疗21天后的NIHSS评分显著低于治疗前(P<0.05或0.01),BI评分均显著高于治疗前(P<0.01);观察组治疗21天后的NIHSS评分和BI评分改善程度均显著优于对照组(P<0.01)。观察组常见的不良反应为低血压,不良反应的发生率为2%(1/50),为尤瑞克林引起,经停药及补液处理后,血压可在短时间内恢复至正常水平。结论尤瑞克林联合单唾液酸四己糖神经节苷脂治疗急性脑梗死疗效肯定,联合用药过程中未见明显不良反应,无配伍禁忌。Objective To investigate efficacy and safety of urinary kallikrein combined with monosialotetrahexosyl ganglioside for acute cerebral infarction. Methods 100 cases of cerebral infarction were randomly divided into observation group and control group with 50 cases in each group.Both groups were given basic treatment according to the disease,and based on which,the observation group were given 0.15 PNAU of urinary kallikrein once a day by intravenous infusion and 100 mg of monosialotetrahexosyl ganglioside once a day for 21 days by intravenous infusion.Results After 21 days of treatment,the efficiency of the observation group was significantly better than that of the control group,difference was statistically significant（ P〈0.01）.Difference of National Institutes of Health Stroke Scale（ NIHSS） and Barthel Index（ BI） score of the two groups before treatment was not statistically significant（ P 〉 0. 05）. After 21 days of treatment,NIHSS was significantly lower than those before treatment（ P〈 0. 05 or 0. 01）,but BI score was significantly higher than those before treatment（ P 〈 0. 01）,both NIHSS and BI score of the observation group improved more significantly than those of the control group（ P〈 0.01）. Common adverse reactions of the observation group was low blood pressure causing by urinary kallikrein,incidence was 2%（ 1 / 50）.After drug withdrawal and rehydration,the blood pressure could restore to normal levels within a short time.Conclusion Urinary kallikrein combined with monosialotetrahexosyl ganglioside has positive effect in the treatment of acute cerebral infarction.No obvious adverse reactions and incompatibility of drugs are found in a prescription during drug combination.

关 键 词：急性脑梗死 尤瑞克林 单唾液酸四己糖神经节苷脂 安全性 

分 类 号：R743.3[医药卫生—神经病学与精神病学]